Skip to main navigation

  • Home
  • About Us
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Suprachoroidal Space
    • SCS Microinjector
    • Publications & Presentations
    • Scientific Advisory Board
  • Pipeline
    • CLS-AX
    • Gene Therapy
    • XIPERE™
  • Collaborations
  • Investors
    • IR Overview
    • News
    • Events & Presentations
    • Governance
    • SEC Filings
    • Financial Info
    • Resources
  • Contact

Linkedin

  • Home
  • About Us
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Suprachoroidal Space
    • SCS Microinjector
    • Publications & Presentations
    • Scientific Advisory Board
  • Pipeline
    • CLS-AX
    • Gene Therapy
    • XIPERE™
  • Collaborations
  • Investors
    • IR Overview
    • News
    • Events & Presentations
    • Governance
    • SEC Filings
    • Financial Info
    • Resources
  • Contact

Linkedin

Investor Relations

  • IR Overview
  • News
  • Events and Presentations
  • Governance
    • Governance Overview
    • Management
    • Board of Directors
    • Committee Composition
  • SEC Filings
  • Financial Info
    • Annual Reports
    • Quarterly Results
    • Analyst Coverage
    • Stock Quote
    • Historical Price Lookup
  • Resources
    • IR Contact
    • Investor Email Signup
    • Investor FAQs

News Releases

News Releases

  • 01/10/13
    Summary ToggleClearside Biomedical Announces Plans for Clinical Testing of CLS1001 (Triamcinolone Acetonide) Suprachoroidal Injectable Suspension for the Treatment of Uveitis
    Releasef0757699-d36f-43fe-9338-7a74457ccfb3_1981140.pdf 9.2 KB
  • 11/06/12
    Summary ToggleClearside Biomedical Announces First Successful Human Dosing – November 6, 2012
    Releaseb72f6291-3086-4e62-93c3-2ccf0414eadd_1981141.pdf 13.7 KB
  • 10/29/12
    Summary ToggleClearside Biomedical Names Charles Deignan Chief Financial Officer
    Releaseff0901e3-c4ae-4ae6-aa9c-1d3a839ea42c_1981143.pdf 9.1 KB
  • 01/25/12
    Summary ToggleClearside Biomedical Launched with Pipeline and Technology Focused on Drugs Delivered to the Back of the Eye
    Release4e0e3fd0-1d7d-4dc4-8bcf-7d1d0f280237_1981144.pdf 17.1 KB

Pagination

First page First Previous page Arrow Page 16 Page 17 Page 18 Current page 19
Displaying 181 - 184 of 184 results

Investor Menu

Footer

Home ABOUT US SCIENCE PIPELINE COLLABORATIONS INVESTORS CAREERS CONTACT PRIVACY

Clearside Biomedical